$
0.000
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation
High
9.300
Open
9.200
VWAP
9.28
Vol
18.76K
Mkt Cap
93.95M
Low
9.200
Amount
173.99K
EV/EBITDA(TTM)
--
Total Shares
113.04M
EV
135.75M
EV/OCF(TTM)
--
P/S(TTM)
13.20
OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
17.70M
+18.95%
--
--
24.20M
+18.11%
--
--
27.60M
+35.05%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for OptiNose, Inc. (OPTN) for FY2025, with the revenue forecasts being adjusted by 13.81% over the past three months. During the same period, the stock price has changed by 45.23%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.81%
In Past 3 Month
Stock Price
Go Up
up Image
+45.23%
In Past 3 Month
3 Analyst Rating
down Image
-3.02% Downside
Wall Street analysts forecast OPTN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPTN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
down Image
-3.02% Downside
Current: 9.280
sliders
Low
9.00
Averages
9.00
High
9.00
HC Wainwright & Co.
Matthew Caufield
Strong Buy
to
Hold
Downgrades
$18 → $9
2025-03-21
Reason
Piper Sandler
David Amsellem
Buy
to
Hold
Downgrades
$15 → $9
2025-03-21
Reason
Piper Sandler downgraded Optinose to Neutral from Overweight with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.
Lake Street
Thomas Flaten
Strong Buy
to
Hold
Downgrades
$17 → $9
2025-03-20
Reason
Lake Street downgraded Optinose to Hold from Buy with a price target of $9, down from $17, after Paratek Pharmaceuticals announced it will be acquiring OptiNose for up to $330M, or $14 per share. Shareholders will be granted contingent value rights worth up to $5 per share, notes the analyst, who expects no additional bids and for the deal to close in mid-2025.
Lake Street
Thomas Flaten
Strong Buy
Maintains
$45 → $17
2025-01-16
Reason
Lake Street analyst Thomas Flaten lowered the firm's price target on Optinose to $17 from $45 and keeps a Buy rating on the shares, saying that "in part accounting for the recent 1-for-15 reverse stock split, we revised our $3 price target to $17" after OptiNose delivered preliminary XHANCE revenue for Q4 of $22.4M, which was above the firm's and consensus estimates.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$5 → $18
2025-01-03
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$5
2024-11-13
Reason

Valuation Metrics

The current forward P/E ratio for OptiNose Inc (OPTN.O) is -3.67, compared to its 5-year average forward P/E of -3.82. For a more detailed relative valuation and DCF analysis to assess OptiNose Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.82
Current PE
-3.67
Overvalued PE
-1.92
Undervalued PE
-5.72

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.22
Current EV/EBITDA
240.71
Overvalued EV/EBITDA
35.07
Undervalued EV/EBITDA
-63.51

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.06
Current PS
0.79
Overvalued PS
2.88
Undervalued PS
1.23

Financials

Annual
Quarterly
FY2024Q4
YoY :
+12.86%
22.42M
Total Revenue
FY2024Q4
YoY :
-114.13%
355.00K
Operating Profit
FY2024Q4
YoY :
-96.39%
-360.00K
Net Income after Tax
FY2024Q4
YoY :
-97.74%
-0.03
EPS - Diluted
FY2024Q4
YoY :
-72.62%
1.87M
Free Cash Flow
FY2024Q4
YoY :
+2.25%
91.28
Gross Profit Margin - %
FY2024Q4
YoY :
+94.66%
-57.21
FCF Margin - %
FY2024Q4
YoY :
-96.79%
-1.61
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 1530.78% over the last month.
Sold
0-3
Months
55.0K
USD
5
3-6
Months
3.4K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
221.9K
USD
7
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
2.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

OPTN News & Events

Events Timeline

2025-04-26 (ET)

News

7.0
04-17Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders
8.5
04-17Globenewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: The AZEK Company Inc. (NYSE - AZEK), Mesa Air Group, Inc. (Nasdaq - MESA), Mr. Cooper Group Inc. (Nasdaq – COOP), Optinose, Inc. (Nasdaq - OPTN)
7.0
04-09PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COOP, MESA on Behalf of Shareholders
8.5
04-08Globenewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: The AZEK Company Inc. (NYSE - AZEK), Mesa Air Group, Inc. (Nasdaq - MESA), Mr. Cooper Group Inc. (Nasdaq – COOP), Optinose, Inc. (Nasdaq - OPTN)
7.0
04-07Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
7.0
04-01PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMST, COOP, OPTN, RDFN on Behalf of Shareholders
8.5
03-31Globenewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mr. Cooper Group Inc. (Nasdaq – COOP), Beacon Roofing Supply, Inc. (Nasdaq - BECN), Optinose, Inc. (Nasdaq - OPTN), Redfin Corporation (Nasdaq - RDFN)
9.5
03-26Newsfilter
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
9.5
03-26SeekingAlpha
OptiNose GAAP EPS of -$0.03 beats by $0.76, revenue of $22.42M beats by $1.6M
7.0
03-23Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders
4.0
03-21Benzinga
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
7.0
03-21Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
4.5
03-20Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase
4.5
03-20Benzinga
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results
8.5
03-20Benzinga
OptiNose Stock Is Soaring Today: What's Going On?
7.0
03-20PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, BECN, OPTN on Behalf of Shareholders
9.5
03-20Benzinga
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
7.5
03-20Benzinga
US Stocks Likely To Open Higher As Fed Says Tariff Induced Inflation Will Be 'Transitory:' Any Pullback In Equities 'Offers An Opportunity,' Says Expert
8.5
03-20SeekingAlpha
OptiNose climbs after take-private deal with Paratek Pharma
7.0
03-20Globenewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Beacon Roofing Supply, Inc. (Nasdaq – BECN), Optinose, Inc. (Nasdaq – OPTN), Corporation (Nasdaq – RDFN), Blackboxstocks Inc. (Nasdaq – BLBX)

FAQ

arrow icon

What is OptiNose Inc (OPTN) stock price today?

The current price of OPTN is 9.28 USD — it has increased 0.22 % in the last trading day.

arrow icon

What is OptiNose Inc (OPTN)'s business?

arrow icon

What is the price predicton of OPTN Stock?

arrow icon

What is OptiNose Inc (OPTN)'s revenue for the last quarter?

arrow icon

What is OptiNose Inc (OPTN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for OptiNose Inc (OPTN)'s fundamentals?

arrow icon

How many employees does OptiNose Inc (OPTN). have?

arrow icon

What is OptiNose Inc (OPTN) market cap?